Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beigene Ltd ADR (NQ: BGNE )

130.46 -1.50 (-1.14%)
Streaming Delayed Price Updated: 3:13 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Beigene Ltd ADR

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
BeiGene to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
From BeiGene
Via Business Wire
PDD Holdings, UP Fintech Holding, Big Lots And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Verizon To Rally Around 20%? Here Are 10 Other Analyst Forecasts For Tuesday
Stifel raised the price target for Hersha Hospitality Trust (NYSE: HT) from $8.75 to $10. Stifel analyst Simon Yarmak downgraded the stock from Buy to Hold. Hersha Hospitality Trust shares fell 0.5% to... 
Via Benzinga
Analyst Expectations for BeiGene's Future
Via Benzinga
Why Are BeiGene Shares Trading Lower Today
BeiGene Limited (NASDAQ: BGNE) shares are trading lower after the company mutually agreed to  
Via Benzinga
BeiGene Ltd. (NASDAQ: BGNE) is a Leading Gainer in Wednesday Morning Trading
Via Investor Brand Network
Who Are Other Players Gaining From Roche's Accidental Lung Cancer Data Update
Earlier today, Roche Holdings AG (OTC: RHHBY) announced that it had been made aware of inadvertent disclosure of the second interim analysis of Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab plus... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 17, 2023
Via Benzinga
Week In Review: BeiGene And Bristol-Myers Squibb Close BeiGene-Celgene PD-1 Partnership
BeiGene and Bristol-Myers Squibb have formally completed the breakup of the BeiGene-Celgene partnership, returning 23.3 million ordinary BeiGene shares to BeiGene. Meanwhile, Gracell Biotechnologies... 
Via Talk Markets
BeiGene Accelerates Global Momentum with Strong Second Quarter 2023 Financial Results
From BeiGene, Ltd.
Via Business Wire
7 Best Cancer Stocks to Invest in Now
The second-largest cause of death in the U.S., more than 600,000 deaths from cancer will occur in 2023. Learn about the best cancer stocks to invest in now. 
Via MarketBeat
Topics Death
Exposures Death
Growing Competition in Hematology, Aesthetics Complicates AbbVie's Post-Humira Landscape, Analyst Says
William Blair has initiated coverage on AbbVie Inc (NYSE: ABBV) with a  
Via Benzinga
Bragar Eagel & Squire, P.C. Is Investigating Viasat and BeiGene and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
BeiGene Announces Positive CHMP Opinion for Tislelizumab as a Treatment for Advanced or Metastatic ESCC
From BeiGene
Via Business Wire
BeiGene's Brukinsa Positioned as Preferred BTK Inhibitor: Analyst Says Survey Supports Bullish View
Citi initiated coverage on BeiGene Ltd (NASDAQ: BGNE) with a price target of $275 and a B 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 17, 2023
Via Benzinga
Bragar Eagel & Squire, P.C. Is Investigating Castle, Coinbase, Arrival, and BeiGene and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus
Regulatory filings show Gilead Sciences' purchase of shares in AlloVir and Arcus. Strategic investments in the biotech sector are fairly common to boost growth. 
Via MarketBeat
Topics Retirement
Exposures Pension
BeiGene Announces FDA Acceptance of sNDA for Fifth BRUKINSA® Indication
From BeiGene
Via Business Wire
Bragar Eagel & Squire, P.C. Is Investigating BeiGene and Fox and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors
From BeiGene
Via Business Wire
BeiGene to Host Investor Research and Development Day in Person and via Webcast on July 18, 2023
From BeiGene
Via Business Wire
Bragar Eagel & Squire, P.C. Is Investigating Fox and BeiGene and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation - BGNE
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
ROSEN, A LEADING LAW FIRM, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation - BGNE
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages BeiGene, Ltd. Investors to Inquire About Securities Class Action Investigation - BGNE
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
Bragar Eagel & Squire, P.C. Is Investigating EPAM, Castle, BeiGene and Fox and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For June 30, 2023
Via Benzinga
Why This BeiGene Analyst Slashes Forecast By Almost 42%
BeiGene Ltd (NASDAQ: BGNE) declined in early trading on Friday, maintaining its downward trajectory through the week amid weakness in Chinese stocks. 
Via Benzinga
NVIDIA To Rally Over 16%? Here Are 10 Other Analyst Forecasts For Friday
Truist Securities boosted the price target for BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from $125 to $140. Truist Securities analyst Robyn Karnauskas maintained a Buy rating. BioMarin Pharmaceutical... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.